Stocks · News reference
8-K filing — ADMA BIOLOGICS, INC. (ADMA)
Filed: 2026-08-05 AccNo: 0001140361-26-031423 Size: 704 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- edgar
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
ADMA Biologics Says Three-Lot Study Shows Updated IVIG Process Removes Clot-Linked Impurities, Raises Yield; No Clotting Events Reported Through July 2026
ADMA Biologics Affirms FY2026 Sales Guidance of $530.000M-$560.000M vs $559.495M Est
ADMA Biologics (NASDAQ:ADMA) affirms FY2026 sales outlook from $530.000 million-$560.000 million to $530.000 million-$560.000 million vs $559.495 million estimate.
ADMA Biologics Q2 Adj. EPS $0.16 Misses $0.17 Estimate, Sales $124.395M Miss $131.658M Estimate
ADMA Biologics (NASDAQ:ADMA) reported quarterly earnings of $0.16 per share which missed the analyst consensus estimate of $0.17 by 5.88 percent. This is a 14.29 percent increase over earnings of $0.14 per share from